PD-L1 Expression in Advanced Osteosarcoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-01

Study Completion Date

2020-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The expression level of PD-L1 on tumor cells is a pivotal point which might have some influence on prognosis, especially for those who might use PD-1 or PD-L1 antibody for treatment. The aim of this study is to detect the expression of PD-1 on advaced osteosarcoma patient who might use these antibodies for treatment. All those specimen should be taken by pathologist and confirmed with high tumor cellularity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prognostic Value of PD-L1 in NSCLC

NCT03078959

Carcinoma, Non-Small-Cell Lung

UNKNOWN

Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients

NCT02758314

Non-Small Cell Lung Cancer

UNKNOWN

Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment

NCT06850506

Sarcoma Sarcoma, Bone Ewing Sarcoma +1 more

ACTIVE_NOT_RECRUITING

A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer

NCT03258788

Non-Small Cell Lung Cancer

COMPLETED

A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens

NCT03092739

Carcinoma, Non-Small-Cell Lung Carcinoma, Small Cell

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Progression Survival

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

observation group

All these patients who have been tested will be observed for further treatment and been recorded for toxicity.

all study participants

Intervention Type OTHER

patients will receive anti-PD-1/anti-PD-L1 antibody for further treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

all study participants

patients will receive anti-PD-1/anti-PD-L1 antibody for further treatment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis confirmed histologically and reviewed centrally;
* received surgery in Musculoskeletal Tumor Center of Peking University People's Hospital with appropriate sample for immunohistochemical staining;
* progressing upon prior treatment (completed \>4 weeks before trial entry) consisted of standard high-grade osteosarcoma chemotherapy agents including doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide; metastatic relapsed and unresectable progressive disease (PD);
* having measurable lesion according to RECIST 1.1;
* Eastern Cooperative Oncology Group performance status 0-1 with a life expectancy \>3 months;
* intend to receive anti-PD-1/anti-PD-L1 antibody for therapy.